Update shared on 09 Nov 2025
Fair value Increased 5.66%Analysts have raised their price target for Tempus AI from $82.50 to $87.17, citing shifts in expected growth and profitability as supporting factors for the updated valuation.
What's in the News
- Tempus AI announced six new abstracts accepted for presentation at the SITC Annual Meeting 2025, highlighting advances in multi-omic algorithms and biomarkers for rare and advanced cancers (Product-Related Announcements).
- The company updated its 2025 earnings guidance, projecting approximately $1.265 billion in revenue, which represents a roughly 80% annual growth rate, following the acquisition of Paige (Corporate Guidance, Raised).
- Tempus AI entered a multi-year collaboration with Whitehawk Therapeutics to use its real-world datasets for advancing biomarker-driven cancer research (Strategic Alliances).
- Selected by ARPA-H, Tempus will provide testing and contract research services for the agency's ADAPT program, supporting innovations in precision oncology (Client Announcements).
- Tempus received FDA 510(k) clearance for its RNA-based Tempus xR IVD device, expanding its offerings in precision diagnostics supporting oncology drug development (Product-Related Announcements).
Valuation Changes
- Consensus Analyst Price Target has risen from $82.50 to $87.17, reflecting a modest increase in projected valuation.
- Discount Rate has increased from 7.39% to 7.95%, indicating a slightly higher perceived risk in future cash flows.
- Revenue Growth expectations have fallen from 31.67% to 27.15%, representing a downward revision in projected growth rate.
- Net Profit Margin has decreased sharply from 12.76% to 3.32%, suggesting a much lower anticipated profitability.
- Future P/E Ratio has jumped significantly from 78.1x to 315.7x, which reflects higher projected valuation relative to future earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.